Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Myeloproliferative neoplasms (incl. CML)
Stage/Subtype:  primary myelofibrosis
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 72 for your search:
Start Over
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PERSIST-2 (PAC326), NCI-2014-00893, NCT02055781
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GS-US-352-0101, NCI-2013-02398, 2013-002707-33, NCT01969838
Busulfan, Fludarabine Phosphate, Total-Body Irradiation, and Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: HEM-05011-L, NCI-2013-00779, CDR0000447204, OHSU-210, OHSU-HEM-05011-L, NCT00245037
Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 1 to 70
Trial IDs: 2005-0781, NCI-2011-02823, RP100469 02, NCT00498316
Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: KB004-01, NCI-2011-00883, NCT01211691
Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide after Donor Bone Marrow Transplant in Treating Patients with Hematological Malignancies
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 6 months to 85
Trial IDs: J1151, NCI-2014-01339, CR00000875, NA_00048378, NA_00048378 / CIR00006178, NCI-2014-00310, NCT01342289
Donor Cytokine-Induced Killer Cells in Treating Patients with Myelodysplasia or Myeloproliferative Disorders Previously Treated with Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 50 and over
Trial IDs: BMT217, NCI-2011-01493, SU-04202010-5724, NCT01392989
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NS-018-101, NCI-2011-03576, NCT01423851
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PRI-724-201, NCI-2012-01153, NCT01606579
Azacitidine in Treating Patients Undergoing Matched Unrelated Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 201303012, NCI-2012-03105, NCT01747499
Ruxolitinib Phosphate and Decitabine in Treating Patients with Myeloproliferative Neoplasms
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MPD-RC 109, NCI-2014-01264, GCO 13-1816, MPD-RC 107, NCT02076191
Palifermin in Preventing Graft-versus-Host Disease in Patients with Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: 15-C-0067, NCI-2015-00084, 00-C-0000, 150067, NCT02356159
Lestaurtinib in Treating Patients With Myelofibrosis
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 104, NCI-2012-00298, NCT00668421
Donor Stem Cell Transplant and T-Cell Infusion with or without Low-Intensity Preparative Chemotherapy using Sirolimus in Treating Patients with Hematologic Malignancies
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: 04-C-0055, NCI-2013-01407, 040055, NCI-2013-01404, NCT00077480, NCI-04-C-0055, NCT00074490
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Phase: Phase II
Type: Treatment
Age: Under 75
Trial IDs: 1825.00, NCI-2010-00230, FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing an Umbilical Cord Blood Transplant for Hematologic Cancer
Phase: Phase II
Type: Treatment
Age: 45 and under
Trial IDs: MT2005-10, NCI-2010-01444, 2005LS043, UMN-2005LS043, UMN-BMT-MT2005-10, UMN-MT2005-10, UMN-0507M71475, NCT00309842
Low-Dose Chemotherapy, Low-Dose Total-Body Irradiation, and Anti-Thymocyte Globulin Followed By Donor Bone Marrow Transplant in Treating Patients With Hematologic Malignancy or Kidney Cancer
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2001-10, NCI-2010-02155, 2001LS058, UMN-2001LS058, UMN-MT2001-10, NCT00303719
Mismatched Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase: Phase II
Type: Treatment
Age: 18 to 65
Trial IDs: IUCRO-0184, NCI-2011-02351, NCT00593554
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients with Hematologic Disease
Phase: Phase II
Type: Treatment
Age: 6 months to 45 years
Trial IDs: 2010.00, NCI-2010-00190, FHCRC 2010.00, Protocol 2010, 6095, NCT00719888
Immune Response after Stem Cell Transplant in HIV-Positive Patients with Hematologic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 75 and under
Trial IDs: 2212.00, NCI-2009-01244, NCT00968630
Rasburicase or Allopurinol in Preventing Tumor Lysis Syndrome in Patients with Hematological Malignancies Undergoing Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2010-0284, NCI-2012-01889, NCI-2010-02082, NCT01200485
Start Over